CLEC2D and neoplasm: Research has demonstrated that LLT1 on tumor cells interacts with the NK cell inhibitory receptor NKRP1A (CD161), leading to the suppression of NK cell-mediated tumor cytotoxicity [39,40,56,57,58,59,60,61,62,63].